AMN Healthcare Services, Inc. — Q1 2022 Form 10-Q
Reporting period: Three months ended March 31, 2022; comparisons are with Q1 2021 unless noted. Amounts below are in millions except per-share data, percentages, and share counts. Financial statements are unaudited.
Business context and results
AMN provides healthcare staffing and workforce solutions through nurse and allied, physician and leadership, and technology and workforce solutions segments. Consolidated revenue rose 75% to $1,552.5 million, reflecting growth across all segments, particularly nurse and allied staffing.
| Metric | Q1 2022 | Q1 2021 |
|---|---|---|
| Revenue | $1,552.5 | $885.9 |
| Gross profit / margin | $496.2 / 32.0% | $288.9 / 32.6% |
| Operating income / margin | $207.9 / 13.4% | $104.4 / 11.8% |
| Net income | $146.0 | $70.4 |
| Diluted EPS | $3.09 | $1.47 |
| Operating cash flow | $200.2 | $39.1 |
| Capital expenditures | $13.6 | $11.6 |
- Revenue by segment: Nurse and allied $1,228.0 million (+87%); physician and leadership $179.5 million (+28%); technology and workforce $145.0 million (+64%). Travel nurse revenue was $970.1 million, up from $498.3 million.
- Margins and expenses: Gross margin declined 0.6 percentage points, mainly due to higher clinician compensation and revenue mix; SG&A rose to $257.6 million but declined as a share of revenue to 16.6% from 18.2%. Net margin increased to 9.4% from 7.9%.
- Cash flow: Operating cash flow improved substantially with higher earnings and working-capital movements. Accounts receivable and subcontractor receivables remained significant cash uses; DSO was 57 days, unchanged year over year.
Financial position, liquidity, and capital allocation
- At March 31, cash and cash equivalents were $113.5 million; total cash, cash equivalents, and restricted cash were $186.1 million. Current assets were $1,478.8 million and current liabilities $1,147.6 million.
- Notes payable, net of fees and premium, were $842.6 million. Face principal comprised $500 million of 4.625% notes due 2027 and $350 million of 4.000% notes due 2029. The $400 million revolving facility had no borrowings and $378.6 million available, subject to facility terms.
- AMN repurchased 2.30 million shares for $228.0 million during the quarter, at an average $99.21 per share. It repurchased a further 718,000 shares for $69.4 million through May 6, 2022. Treasury shares increased, while total stockholders’ equity fell to $1,080.9 million from $1,162.0 million at year-end.
- Management said operating cash generation and available revolver borrowings should fund operations and liquidity needs, including expected capital expenditures, for the next 12 months and beyond.
Changes, outlook, and management commentary
- Nurse and allied growth reflected a 41% increase in average travelers on assignment and an approximately 35% increase in average bill rates. Physician and leadership growth included higher locum tenens days filled; technology growth was led by vendor management systems.
- Management reported historically high staffing demand, while noting travel nurse demand had begun to moderate from crisis levels but remained above pre-pandemic levels. Nurse wages and bill rates peaked in Q1; management expected rates to decline from Q1 levels but remain well above pre-pandemic levels through the rest of 2022. No consolidated revenue or earnings guidance is provided in the supplied filing text.
- Allied staffing demand reached a record, and physician/leadership demand exceeded pre-pandemic levels. Management expected continued demand for locum tenens, interim leadership, and recruitment process outsourcing. VMS utilization and bill rates could subside as COVID-19 hospitalizations declined, while remaining above pre-pandemic levels.
- AMN estimated a 27% annual effective tax rate for 2022; the Q1 rate was 26%, including a $1.9 million discrete stock-compensation tax benefit.
- Synzi and SnapMD, acquired in April 2021 for an initial $42.2 million cash purchase price, contributed to comparability and are included in technology and workforce solutions.
Risks, contingencies, and unusual items
- The company had accrued $37.2 million for significant wage-and-hour matters. A separate Woehrle matter had a settlement agreement awaiting court approval, with final settlement not expected until Q4 2022. AMN said it could not estimate possible losses beyond recorded accruals.
- AMN cited uncertainty around pandemic effects, staffing demand and bill rates, clinician recruitment and retention, inflation and economic conditions, client payment and receivables, regulation and worker classification, litigation, cybersecurity and technology, acquisitions, and indebtedness.
- A Dallas office lease signed during the quarter has approximately $29.5 million of future undiscounted payments; it is expected to commence in Q1 2023, when the lease asset and liability will be recorded.
- CEO Susan R. Salka’s planned retirement by year-end 2022 or earlier upon appointment of a successor was followed by a May 5 transition agreement, including eligibility for her 2022 annual bonus at the maximum level and a planned three-year advisory agreement after separation.
Important facts for investors to verify
- Whether travel nurse demand, clinician compensation, and bill rates moderated as management anticipated—and the resulting effect on staffing volume and gross margins.
- Whether elevated receivables and working-capital requirements convert into sustained operating cash flow; track DSO and subcontractor receivables.
- Debt terms, revolver availability, and liquidity after substantial share repurchases and subsequent repurchases through May 6.
- Developments, settlement approval, and any additional exposure in the wage-and-hour litigation relative to the $37.2 million accrual.
- Leadership transition and incentive arrangements, including the planned CEO departure and the CFO equity-agreement amendments.